CN114642658A - Oil-soluble micromolecule natural biological acid antiviral and antibacterial preparation, and preparation method and application thereof - Google Patents
Oil-soluble micromolecule natural biological acid antiviral and antibacterial preparation, and preparation method and application thereof Download PDFInfo
- Publication number
- CN114642658A CN114642658A CN202210078117.6A CN202210078117A CN114642658A CN 114642658 A CN114642658 A CN 114642658A CN 202210078117 A CN202210078117 A CN 202210078117A CN 114642658 A CN114642658 A CN 114642658A
- Authority
- CN
- China
- Prior art keywords
- oil
- formic acid
- acid
- soluble
- oxalic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
- A41D13/1192—Protective face masks, e.g. for surgical use, or for use in foul atmospheres with antimicrobial agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Textile Engineering (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an antiviral and antibacterial oil-soluble preparation of micromolecule biological acids, which contains the micromolecule biological acids as effective medicinal ingredients, wherein the micromolecule biological acids are dissolved in an oil-oil mutual solution or an oil-water mutual solution, and the oil-oil mutual solution or the oil-water mutual solution is oil which is mutually soluble with the micromolecule biological acids, so that the antiviral and antibacterial oil-soluble preparation of the micromolecule biological acids is obtained. The preparation is prepared into micromolecular biological acid antiviral and antibacterial drugs with various dosage forms by being mixed with medicinal excipients. The medicine can be used as medicine for resisting rhinovirus, influenza virus and other viruses and germs which often infect people, and can also be used as medicine for preventing and treating novel coronavirus infection.
Description
Technical Field
The invention relates to the field of biological pharmacy, and particularly provides an oil-soluble micromolecule natural biological acid antiviral and antibacterial preparation and a preparation method thereof. The preparation provided by the invention can be used as a medicine for preventing and treating antivirus and antibiosis. In particular, it has important preventive and therapeutic effects on infection with a pathogen such as a novel coronavirus (COVID-19), an influenza virus, or a rhinovirus.
Background
The virus is invisible to the naked eye but very active in the earth ecosystem. Viruses also regulate the survival of a large number of living organisms, none of which is affected from microorganisms to large mammals. The effects of viruses are not limited to organisms, but they can also affect the climate, soil, ocean and fresh water of the earth. In 2009, scientists dana wilna discovered that on average, many 174 viruses were harbored in the human lungs, only 10% of which were relatives of the viruses found, and the other 90% of which were strange (see [ american ] clazimer; liu 26104; virus star 4 months 2019; university press of cantonese university; 001,004,005).
Newspaper and periodical data: respiratory viruses that frequently infect humans are over 200. There are more than 70 enteroviruses that often infect humans. Some enteroviruses also cause respiratory infections. Respiratory infections are 95% caused by viruses. "there are more than 400 viruses that can infect humans". More than 200 kinds of anti-virus antibodies can be detected by an ordinary adult.
The ability to make defensive substances resistant to various microorganisms, not exclusively present in animals; i.e., the subgenus, and even bacteria (Pasteur and Joubert, 1877) can sometimes produce substances that inhibit or prevent the growth of other species of microorganisms. These substances are generally known as Antibiotics (Antibiotics), which are widely available in nature, but in recent times, the prescription is introduced into the therapeutic world to exert the great effect (see the Puer Sunju; Zhao Zhan, Pharmacology, datebook 1956; commercial library; 637.). This is the definition of the originality of penicillin on the market with respect to antibiotics.
Through long-term natural selection, formic acid (formic acid), oxalic acid (oxalic acid), propionic acid, lactic acid, citric acid, sorbic acid, benzoic acid and the like become main natural defense substances of animals and plants.
Formic acid is a defensive substance which is naturally selected by ants and bees for a long time and inhibits or hinders the growth of other species of microorganisms. Is the main component of defense function of 2 ten thousand kinds of bees and 1 ten thousand kinds of ants on the earth.
Oxalic acid exists in free state of potassium salt and calcium salt in plant, especially wood of arbor and bush, and can prevent arbor and bush from being damaged by putrefactive microbe.
Sorbic acid, benzoic acid, and the like are defense substances for various plants. Before fruits are ripe, the concentration of various biological acids is higher, so that the invasion of microorganisms to the fruits is prevented, and the fruits are not easy to rot; after the fruit is cured, the biological acid substances are reduced, the acidity is reduced, the defense effect of the biological acid on microorganisms is reduced, and the fruit is easy to rot.
In recent centuries, the above-mentioned defensive substances derived from animals and plants have become widely used food additives, disinfectants, antiseptics and industrial medicinal materials.
However, no report has been found so far for the research of using the biological acids with the strongest disinfection and antiseptic potency, such as formic acid, oxalic acid, lactic acid, etc., to prepare oil-soluble preparations with smaller application dosage for treating influenza.
Disclosure of Invention
The invention classifies the defense substances produced by animals and plants, which have small molecular weight and are antiviral and antibacterial, formed by long-term natural selection into small molecular biological acids, and the biological acids can also be called animal and plant life acids. The invention recognizes that series of small molecule biological acids such as formic acid, oxalic acid, lactic acid, propionic acid, sorbic acid, benzoic acid and the like are water-soluble and can also be used for preparing the biological acid antibiotics which become oil-soluble preparations.
The inventors of the present invention have studied the antiviral and antibacterial properties of oil-soluble small-molecule biological acids, and specifically, the small-molecule biological acids which are mainly studied by experiments of the present invention include:
formic acid, also known as formic acid, is present in the secretions of bees, some ants and some caterpillars. Originally obtained from distilled ants, the simplest fatty acid. The molecular formula is HCOOH. Melting point 8.4 deg.C, boiling point 100.5 deg.C, molecular weight 46.03, colorless and pungent liquid, and inflammable. Can be freely mixed and dissolved with water, ethanol, ether and glycerin, is mixed and dissolved with most polar organic solvents, and also has certain solubility in hydrocarbon. And is corrosive, and the skin of human beings can blister and swell after contacting. In the chemical industry, formic acid is used in the rubber, pharmaceutical, dye, leather-like industries. Used for producing acetate and acetate (see Wang apothelin code, chemical dictionary, 4 th edition; (2000); (chemical industry Press; 443)), and also used as a disinfectant and antiseptic. It is the most acidic saturated monocarboxylic acid.
"ADI value" is the maximum intake amount that can be ingested continuously daily without affecting health in a person's lifetime, as described in the handbook of food additives. Formic acid as a food additive has an ADI of 0-3 mg/kg (FAO/WHO,1973) (see the great news of the family, the treatise on the tide, book of food additives (1989); chemical industry Press 5; page 168 03559), i.e. a maximum daily dosage of 180mg per 60kg body weight.
Formic acid is present in the poison control devices of several insects (e.g. the Formica rufa, red ants), which have been used in rheumatism and neuralgia in the Western world in the form of so-called ant baths, i.e. by exploring the ant dunes (and the ants therein).
Oxalic acid, i.e., oxalic acid, molecular weight: 126.07, respectively; the potassium salt and calcium salt are widely present in plants, particularly Rheum (Rheum genus) and Spinacia (Spinacia genus), in a free state, and are widely present in the wood of trees and shrubs. "the human body is under normal condition, and does not produce oxalic acid; oxalic acid, which is usually 20.0mg in daily urine, is not produced, but is frequently produced in livestock and poultry (see Puer Sunjiang; Zhao teacher Zhao Ji; (pharmacology) brochure 1956; commercial brochure, 426). Oxalic acid is the most important chemical raw material, and is used for medicine production, polymer synthesis and the like. The old method uses wood chips as raw material and is prepared by alkali fusion to sodium oxalate (see Wang apothecary, chemical dictionary, 2 nd edition; (1979); (chemical industry Press; 385).
According to the records of the TCM parent Zhang Xi Chun (Chinese medicine affinity reagent) by Chinese modern Chinese medical scientists, rhubarb is a specific traditional Chinese medicine for treating furunculosis. In recent medicine, the traditional Chinese medicine containing oxalic acid has been used as a specific traditional Chinese medicine for treating furunculosis.
Lactic acid, a colorless to pale yellow syrupy liquid, almost odorless, or slightly odorous with fatty acids, strongly acidic in flavor, miscible with water, propylene glycol, glycerol, acetone, diethyl ether and ethanol. Is widely used for flavoring and preventing food corrosion (Ling guan Wang Yu, Tang Huo Ji, book of food additive handbook (1989); chemical industry Press, 262 p 05007).
Modern western medicine "pharmacology" records: before the 50 s of the 20 th century, western European hospitals applied lactic acid solutions to oral administration, so that the lactic acid solutions often have good effects on treating infantile diarrhea; adult can be used for treating diarrhea by orally administering 5% lactic acid; it is also recorded that 20% lactic acid is applied to the affected part to treat tuberculosis of larynx (see Puer Sunzhe; Zhao teacher Zhao Zhan; Pharmacology 1956; Business brochure, 423).
The external genital tract of female mammal is grown with lactobacillus, which can prevent virus and germ from invading body from external genital tract, to protect health of mammal. The literature states that 0.18% lactic acid can kill escherichia coli; 0.36% lactic acid can kill the growth of staphylococcus.
The water-soluble preparation of the small molecular biological acid is quickly discharged out of a human body from a urinary tract, the concentration of medicaments in a respiratory system and a digestive system is low, and the concentration of antiviral and antibacterial medicaments in targets of the respiratory system and the digestive system in the human body can not be achieved. In order to solve the pharmaceutical and pharmacological difficulties, the invention selects oil-oil mutual solution and oil-oil mutual solution as solvent carrier of small molecular biological acid, and develops the oil-soluble formic acid antiviral preparation successfully.
The literature describes the use of formic acid as a food additive for disinfection and preservation, in a maximum daily dose of 180mg per 60kg body weight (ADI of 0 to 3 mg/kg). The oil-soluble formic acid oral preparation and the transdermal absorbent developed by the inventor of the invention have the daily dosage of 8-16mg for 60kg of body weight, which is reduced by 10 times compared with the maximum daily dosage of 180mg of water-soluble formic acid oral preparation and the transdermal absorbent serving as food additives. Clinical practice for treating influenza proves that the oil-soluble formic acid preparation has obvious antiviral effects of relieving nasal obstruction and relieving cough and easily expectorating phlegm for treating influenza.
After the micromolecule biological acid-oil-soluble and oil-water-soluble preparation is applied, in the processes of pharmacokinetic absorption, distribution and excretion, the dynamic drug concentration of a digestive system (liver, gallbladder and intestine) and a respiratory system (lung and trachea) is higher, the discharge amount of a urinary system is less, and the treatment dosage does not generate toxic and side effects.
The microorganism has drug resistance to biological acid with small molecular weight and stable physical and chemical properties, and has poor biological function. Therefore, pathogenic microorganisms are not easy to generate drug resistance to small molecular biological acid. For example: the microorganism is not easy to generate drug resistance to lactic acid, formic acid and acetic acid.
When the oil agent is selected, only one oil agent is used, the optimal requirements of small molecular biological acid pharmacy, pharmacology and toxicology can not be met, and the oil agent conforming to the physicochemical property of the small molecular biological acid is selected from various oil agents, so that the aim of obviously improving the pharmacological action is fulfilled.
There are 1700 kinds of spices recognized to be safe for eating abroad at present, which are described in a handbook of synthetic practical spices. The method comprises the following steps: hydrocarbons and their derivatives, alcohols, ethers, phenols and their derivatives, aldehydes, acetals, ketones, lactones, acids, esters, sulfur-and nitrogen-containing compounds … …. Through years of experimental research, the invention finds that only the essential oil of alcohols, ketones and esters is suitable to be used as a solvent carrier of small molecular biological acid, and has certain practicability.
Based on the above studies, in order to provide a small molecule biological acid drug which can be used for preventing and treating infection of various viruses and bacteria such as rhinovirus, influenza virus, novel coronavirus and the like, the first aspect of the present invention is to provide an antiviral and antibacterial oil-soluble preparation of a small molecule biological acid, which comprises a small molecule biological acid as an effective drug ingredient, wherein the small molecule biological acid is dissolved in an oil-oil mutual solution or an oil-water mutual solution, and the oil-oil mutual solution or the oil-water mutual solution is an oil which is miscible with the small molecule biological acid, so as to obtain the antiviral and antibacterial oil-soluble preparation of the small molecule biological acid. The micromolecule biological acid oil-soluble preparation and medicinal excipient are prepared into micromolecule biological acid antiviral and antibacterial medicines with various dosage forms. The medicine can be used as medicine for resisting rhinovirus, influenza virus and other viruses and germs which often infect people, and is the first choice for preventing and treating novel coronavirus infection.
Preferably, the oil-in-water or oil-in-oil miscible oils contain essential oils of the alcohol, ketone and/or ester type.
Preferably, the small molecule biological acid comprises formic acid (formic acid), oxalic acid (oxalic acid), lactic acid, propionic acid, sorbic acid or benzoic acid.
Preferably, the essential oil comprises: esters such as ethyl oleate, methyl phenylacetate and tristearin, ketones such as 2-butanone, 2-pentanone, 3-heptanone and levocarvone, alcohols such as propylene glycol, glycerol, benzyl alcohol and octadecanol, and stearic acid.
In a second aspect of the present invention, there is provided a transdermal absorption varnish containing formic acid as an effective pharmaceutical ingredient, the formic acid solvent carrier being an oil-oil mutual solution, comprising:
formic acid: 1440.0-1920.0mg
Ethyl oleate: 259.2-345.6g
Ketone essential oil: 28.8-38.4g
Ester essential oil: 28.8-38.4g
Octadecanol: 40.0-80.0g
Stearic acid: 40.0-80.0g
Emulsifier (Tween-80) 70.0-90.0g
The total amount of the rest of distilled water is 1200.0g
Preparing transdermal absorption liniment containing formic acid 1.2-1.6mg per gram.
In a third aspect of the present invention, there is provided a formic acid intravenous drip containing formic acid as an effective pharmaceutical ingredient, wherein a formic acid solvent carrier is an oil-water miscible liquid, comprising:
formic acid: 600.0-800.0mg
2-butanone: 120.0-160.0g
2-pentanone: 12.0-16.0g
3-heptanone: 12.0-16.0g
The balance of physiological water for injection, the total amount of liquid is 25000.0ml, and the intravenous drip agent with one dose of 6.0-8.0mg formic acid per 250ml drip agent is prepared.
In a fourth aspect of the present invention, there is provided a formic acid oral capsule containing formic acid as an effective pharmaceutical ingredient, wherein the formic acid solvent carrier is an oil-oil miscible body, comprising:
formic acid: 12000.0mg
Ethyl oleate: 1320.0g
Methyl phenylacetate: 480.0g
Gluten powder: 4788.0g
The total amount of the prepared materials is as follows: 12000 capsules, each 0.55g, each containing 1.0mg formic acid.
In a fifth aspect of the present invention, there is provided a formic acid oil-soluble oral soft capsule containing formic acid as an effective pharmaceutical ingredient, wherein the formic acid solvent carrier is an oil-oil mutual solution comprising:
formic acid: 6000.0mg
Ethyl oleate: 660.0g
Methyl phenylacetate: 240.0g
Glyceryl tristearate: 300.0g
The soft capsule is prepared from appropriate amount of materials such as gelatin, Arabic gum and plasticizer: 6000 capsules of formic acid oil-soluble oral soft capsule, each containing 1.0mg of formic acid.
In a sixth aspect of the present invention, there is provided an oil-soluble formic acid oral pill containing formic acid as an effective pharmaceutical ingredient, wherein the formic acid solvent carrier is an oil-oil mutual solution comprising:
formic acid: 12000.0mg
Ethyl oleate: 1320.0g
Methyl phenylacetate: 480.0g
Starch: proper amount of
Gluten powder: proper amount of
Chinese bee honey: proper amount of
Making into oral formic acid pill 2000 g (6.15 g/pill) containing formic acid 6.0 mg/pill.
Because the Chinese bee honey belongs to the raw material medicines of the traditional Chinese medicine, the pill can also be called a pill combining traditional Chinese medicine and western medicine.
The seventh aspect of the present invention provides an oxalic acid oil-soluble oral soft capsule, containing oxalic acid as an effective pharmaceutical ingredient, characterized in that the oxalic acid solvent carrier is an oil-oil mutual solution, comprising:
oxalic acid: 4500.0-6000.0 mg
Methyl phenylacetate: 720.0-960.0 g
Levo carvone: 225.0-300.0 g
Glyceryl tristearate: 150.0-280.0g
The soft capsule is prepared from appropriate amount of materials such as gelatin, Arabic gum and plasticizer: the total amount of the oxalic acid oil-soluble oral soft capsule is 3000 capsules, each capsule contains 1.5-2.0 mg of oxalic acid, 2 times a day and 2 capsules each time. 6.0-8.0mg per day.
The eighth aspect of the present invention provides an oil-soluble oxalic acid oral pill, containing oxalic acid as an effective pharmaceutical ingredient, characterized in that the oxalic acid solvent carrier is an oil-oil mutual solution, comprising:
oxalic acid: 5200.00-7600.0mg
Methyl phenylacetate: 832.00-1216.0g
Levo carvone: 260-380.0g
Starch: 2225.7-2098.0g
Gluten powder: 2225.7-2098.0g
Chinese bee honey: 4451.0-4197.0g
Making into oral pill of oxalic acid 2000 g, 5.0g each pill, 2.6-3.8mg each pill.
The ninth aspect of the invention provides lactic acid oil-soluble disinfection protective mask liquid, which contains lactic acid as an effective medicinal component and is characterized in that a lactic acid solvent carrier is an oil-water mutual solution and comprises the following components:
lactic acid: 25.0-42.0g (accounting for 0.25-0.42% of the total weight)
Glycerol: 9863.0-9732.0g
Benzyl alcohol: 10.0-20.0g (accounting for 0.1-0.2% of the total weight)
The balance of distilled water: 100.0-200.0 g. 10000ml of lactic acid oil-soluble protective mask liquid is prepared. Spraying the obtained solvent on the carrier to obtain the mask containing lactic acid solution.
The tenth aspect of the present invention provides a formic acid oil-soluble protective mask solution, which contains formic acid as an effective pharmaceutical ingredient, and is characterized in that the formic acid solvent carrier is an oil-water mutual solution, and comprises the following components:
formic acid: 1.0-2.0 g (0.01-0.02% of the total amount)
Glycerol: 9799.0-9598.0g
Propylene glycol: 100.0-200.0g (1-2% of the total amount)
The balance of distilled water: 100.0-200.0 g. 10000ml of formic acid oil-soluble protective mask liquid is prepared. Spraying the obtained solvent on carrier to obtain protective mask or wet towel containing formic acid solution.
The eleventh aspect of the invention provides oxalic acid oil-soluble protective mask liquid, which contains oxalic acid as an effective medicinal component and is characterized in that an oxalic acid solvent carrier is an oil-water mutual solution and comprises the following components:
oxalic acid: 6.0-12.0g (0.06-0.12% of the total amount)
Glycerol: 9794.0-9588.0g
Propylene glycol: 100.0-200.0g (1-2% of the total)
The balance of distilled water, and 10000ml of oxalic acid oil-soluble protective mask liquid is prepared. Spraying the obtained solvent on the carrier to obtain the mask containing oxalic acid solution.
In a twelfth aspect of the present invention, there is provided a formic acid antibiotic solution for preparing an inactivated vaccine against a neo-coronavirus ecological antibiotic, wherein the solution is an inactivated oral vaccine prepared from a formic acid oil-oil mutual solution, a formic acid oil-water mutual solution, and an oxalic acid or lactic acid oil-oil mutual solution.
The technical solution of the present invention will be further described below by way of examples.
Detailed Description
The exemplary embodiments will be described herein in detail, and the embodiments described in the following exemplary embodiments do not represent all embodiments consistent with the present invention. They are merely examples of small molecule biological acid oil-in-oil solubilities, oil-in-water solubilities, and methods of formulating the same, consistent with certain aspects of the invention, described in further detail.
The starting materials used in the following examples:
1. the formic acid and other small molecular biological acid raw materials are superior products obtained by the prior art.
2. Other raw materials are refined industrial products.
Example 1
The transdermal absorption coating agent of the oil-oil mutual dissolving body is prepared by the following components:
formic acid: 1440.0-1920.0mg
Ethyl oleate: 259.2-345.6g
Ketone essential oil: 28.8-38.4g
Ester essential oil: 28.8-38.4g
Octadecanol: 40.0-80.0g
Stearic acid: 40.0-80.0g
Emulsifier (Tween-80) 70.0-90.0g
The total amount of the rest distilled water is 1200.0g
Preparing transdermal absorption liniment containing formic acid 1.2-1.6mg per gram.
A60 kg adult applies the skin absorption liniment 3.0g on chest, back and limbs health skin 3 times per day, and the skin absorption liniment contains formic acid 10.08-14.4 mg. The preparation enters blood circulation through lymphatic system, has high drug concentration at respiratory tract and intestinal tract target, and has remarkable curative effect in treating respiratory system infection such as influenza. Can be preferably used for treating infection of virus and germ such as rhinovirus, influenza virus, new type coronavirus, etc.
Example 2
The formic acid intravenous drip agent is prepared by the following components:
formic acid: 600.0-800.0mg
2-butanone: 120.0-160.0g
2-pentanone: 12.0-16.0g
3-heptanone: 12.0-16.0g
The balance of physiological water for injection, the total amount of liquid is 25000.0 ml; making into intravenous drip containing formic acid 6.0-8.0mg per 250ml drip.
Is applied to patients who are not suitable for transdermal absorbent and oral preparation. The injection is administered by intravenous drip for 2 times daily, and the amount of formic acid is 12.0-16.0mg per day. Can be used for treating severe patients infected by viruses and germs such as novel coronavirus and influenza virus.
Example 3
Preparing the formic acid oral capsule, which comprises the following components:
formic acid: 12000.0mg
Ethyl oleate: 1320.0g
Methyl phenylacetate: 480.0g
Gluten powder: 4788.0g
The total amount of the prepared materials is as follows: 12000 capsules with the weight of 0.55g each and containing 1.0mg of formic acid are taken orally.
The formic acid dosage is about 8.0-12.0mg per day for 60kg adult, 2 times per day, 4-6 capsules per time. Can be preferably used for treating infection of virus and germ such as rhinovirus, influenza virus, new type coronavirus, etc.
Example 4
The formic acid oil soluble oral soft capsule is prepared by the following components:
formic acid: 6000.0mg
Ethyl oleate: 660.0g
Methyl phenylacetate: 240.0g
Glyceryl tristearate: 300.0g
The soft capsule is prepared from appropriate amount of materials such as gelatin, Arabic gum and plasticizer: 6000 capsules of formic acid oil-soluble oral soft capsule, each containing 1.0mg of formic acid.
The 60kg adult treats respiratory system virus and bacterial infection 2 times a day, 4-6 capsules each time. Corresponding to 8.0-12.0mg of pure formic acid. Can be used for treating and preventing influenza and novel coronavirus infection.
Example 5
The oil-soluble formic acid oral pill is prepared from the following components:
formic acid: 12000.0mg
Ethyl oleate: 1320.0g
Methyl phenylacetate: 480.0g
Starch: proper amount of
Gluten powder: proper amount of
Chinese bee honey: proper amount of
Making into oral formic acid pill 2000 g (6.15 g/pill) containing formic acid 6.0 mg/pill.
60kg for adult, 2 times daily, 1 pill each time. Can be preferably used for treating and preventing infection of virus and germ such as novel coronavirus and influenza virus. Because the Chinese bee honey belongs to the raw material medicines of the traditional Chinese medicine, the pill can also be called a pill combining traditional Chinese medicine and western medicine.
Example 6
Preparing the oxalic acid oil soluble oral soft capsule, which comprises the following components:
oxalic acid: 4500.0-6000.0 mg
Methyl phenylacetate: 720.0-960.0 g
Levo carvone: 225.0-300.0 g
Glyceryl tristearate: 150.0-280.0g
The soft capsule is prepared from appropriate amount of materials such as gelatin, Arabic gum and plasticizer: 3000 capsules of oxalic acid oil soluble oral soft capsule, each capsule contains 1.5-2.0 mg of oxalic acid. The dosage is 2 granules per time for adult 2 times per day, i.e. the content of oxalic acid is 6.0-8.0 mg. Can be used for treating and preventing respiratory tract infection of new type coronavirus, influenza virus and other viruses and germs which commonly infect human.
Example 7
The oil-soluble oxalic acid oral pill is prepared by the following components:
oxalic acid: 7600.0mg
Methyl phenylacetate: 1216.0g
Levo carvone: 380.0g
Starch: 2098.0g
Gluten powder: 2098.0g
Chinese bee honey: 4197.0g
Making into oxalic acid oral pill 2000 pills, each pill is 5.0g, and each pill contains oxalic acid 3.8 mg.
Example 8
Lactic acid oil-soluble protective mask liquid comprises the following components:
lactic acid: 25.0-42.0g (accounting for 0.25-0.42% of the total weight)
Glycerol: 9863.0-9732.0g
Benzyl alcohol: 10.0-20.0g (accounting for 0.1-0.2% of the total weight)
The balance of distilled water, and 10000ml of lactic acid oil-soluble protective mask liquid is prepared. Spraying the obtained solvent on a carrier to obtain the protective mask containing the lactic acid oil-soluble liquid.
Example 9
The formic acid oil soluble disinfecting protective mask liquid comprises the following components:
formic acid: 1.0-2.0 g (0.01-0.02% of the total amount)
Glycerol (b): 9799.0-9598.0g
Propylene glycol: 100.0-200.0g (1-2% of the total amount)
The balance of distilled water, and 10000ml of formic acid oil-soluble disinfection protective mask liquid is prepared. Spraying the obtained solvent on carrier to obtain disinfectant mask and wet towel containing formic acid solution.
Example 10
An oxalic acid oil-soluble protective mask liquid comprises the following components:
oxalic acid: 6.0-12.0g (accounting for 0.06% -0.12% of the total amount)
Glycerol: 9794.0-9588.0g
Propylene glycol: 100.0-200.0g (1-2% of the total amount)
The balance of distilled water, and 10000ml of oxalic acid oil-soluble protective mask liquid is prepared. And spraying the obtained solvent on a carrier to prepare the protective mask containing the oxalic acid solution.
Examples of clinical applications
The preparation prepared by the invention is clinically used and has obvious effect.
1. For 5 suspected persons with obvious symptoms of the new coronavirus, the formic acid oral capsule prepared in example 3 was used, and the formic acid dosage per day was about 12.0mg, 2 times per day, 6 capsules per time, per 60kg adult. 6.0mg is applied every time, and after 12 hours of application, the symptoms of nasal obstruction and fever disappear, and the cough symptom is relieved. After 24 hours, the sputum is more likely to be expectorated. After 3 days of administration, the subjective symptoms disappeared and administration was stopped.
2. For 12 of the patients with common symptoms, watery nasal discharge, nasal obstruction, general weakness and cough, the formic acid pill prepared in example 5 is applied for 2 times a day, 1 pill is applied every time, 6.0mg is applied every time, after 1 day of application, symptoms of fatigue, cough, watery nasal discharge and nasal obstruction are relieved, and after 4 days of application, the subjective symptoms of the patients disappear and the administration is stopped.
3. The oil-soluble epidemic prevention mask liquid containing lactic acid and formic acid prepared in example 8 and example 9 was applied to 20 workers and their relatives of the same applicant company, and the liquid was uniformly sprayed on the outer layer of a disposable mask before the flow (business trip) of the workers, and the mask was discarded and replaced for 2 to 4 days. The epidemic situation epidemic area in China flows (goes on business), and through a plurality of experiments, people using the epidemic prevention mask keep healthy, and no new coronavirus nucleic acid positive test person appears.
Clinical application results of the application of the invention show that the invention has important prevention and treatment effects on the infection of viruses and germs such as novel coronavirus, influenza virus and the like.
Other embodiments of the present invention will readily suggest themselves to such skilled persons having the benefit of this disclosure. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
It will be understood that the invention is not limited to the precise arrangements described above and that various modifications and changes may be made without departing from the scope thereof. The scope of the invention is limited only by the claims.
Claims (14)
1. An antiviral, antibacterial and oil-soluble preparation of small molecule biological acids, which contains small molecule biological acids as effective medicinal ingredients, is characterized in that the small molecule biological acids are dissolved in oil-oil mutual solution or oil-water mutual solution, and the small molecule biological acids comprise: formic acid, oxalic acid, lactic acid, propionic acid, sorbic acid or benzoic acid, and the oil-oil mutual solution or the oil-oil mutual solution is oil which is mutually soluble with small molecular biological acid.
2. The antiviral and antibacterial agent of claim 1, wherein said oil comprises: essential oils of the oil esters, alcohols, ketones and/or lactones type.
3. The antiviral and antibacterial agent of claim 2, wherein said essential oil comprises: one or more of oleic acid esters such as ethyl oleate, methyl phenylacetate and tristearin, ketones such as 2-butanone, 2-pentanone, 3-heptanone and levocarvone, alcohols such as propylene glycol, glycerol, benzyl alcohol and octadecanol, and stearic acid.
4. A percutaneous absorption liniment contains formic acid as an effective medicinal component, and is characterized in that a formic acid solvent carrier is an oil-oil mutual solution and comprises the following components:
formic acid: 1440.0-1920.0mg
Ethyl oleate: 259.2-345.6g
Ketone essential oil: 28.8-38.4g
Ester essential oil: 28.8-38.4g
Octadecanol: 40.0-80.0g
Stearic acid: 40.0-80.0g
Emulsifier (Tween-80) 70.0-90.0g
The total amount of the rest of distilled water is 1200.0g
Preparing transdermal absorption liniment containing formic acid 1.2-1.6mg per gram.
5. The intravenous injection of formic acid contains formic acid as effective medicine component and features that the formic acid solvent carrier is oil-water mutual solution comprising the following components:
formic acid: 600.0-800.0mg
2-butanone: 120.0-160.0g
2-pentanone: 12.0-16.0g
3-heptanone: 12.0-16.0g
The balance of physiological water for injection: total amount of liquid 25000.0 ml; making into intravenous drip containing formic acid 6.0-8.0mg per 250 ml.
6. A formic acid oral capsule contains formic acid as effective pharmaceutical ingredient, characterized by that, formic acid solvent carrier is oil-oil mutual solution, according to the following ingredients:
formic acid: 12000.0mg
Ethyl oleate: 1320.0g
Methyl phenylacetate: 480.0g
Gluten powder: 4788.0g
The total amount of the prepared materials is as follows: 12000 capsules with the weight of 0.55g each and containing 1.0mg of formic acid are taken orally.
7. The oral formic acid oil soluble soft capsule contains formic acid as effective medicine component and features that the formic acid solvent carrier is oil-oil mutual solvent comprising the following components:
formic acid: 6000.0mg
Ethyl oleate: 660.0g
Methyl phenylacetate: 240.0g
Glyceryl tristearate: 300.0g
The soft capsule is prepared from appropriate amount of materials such as gelatin, Arabic gum and plasticizer: 6000 capsules of formic acid oil-soluble oral soft capsule, each containing 1.0mg of formic acid.
8. An oil-soluble formic acid oral pill contains formic acid as an effective medicinal component, and is characterized in that a formic acid solvent carrier is an oil-oil mutual solution and comprises the following components:
formic acid: 12000.0mg
Ethyl oleate: 1320.0g
Methyl phenylacetate: 480.0g
Starch: proper amount of
Gluten powder: proper amount of
Chinese bee honey: proper amount of
Making into oral formic acid pill 2000 g (6.15 g/pill) containing formic acid 6.0 mg/pill.
9. An oxalic acid oil-soluble oral soft capsule contains oxalic acid as an effective medicinal component, and is characterized in that an oxalic acid solvent carrier is an oil-oil mutual solution and comprises the following components:
oxalic acid: 4500.0-6000.0 mg
Methyl phenylacetate: 720.0-960.0 g
Levo carvone: 225.0-300.0 g
Glyceryl tristearate: 150.0-280.0g
The soft capsule is prepared from appropriate amount of materials such as gelatin, Arabic gum and plasticizer: the total amount of the oxalic acid oil-soluble oral soft capsule is 3000 capsules, and each capsule contains 1.5-2.0 mg of oxalic acid.
10. An oil-soluble oxalic acid oral pill contains oxalic acid as an effective medicinal component, and is characterized in that an oxalic acid solvent carrier is an oil-oil mutual solution and comprises the following components:
oxalic acid: 7600.0mg
Methyl phenylacetate: 1216.0g
L-carvone: 380.0g
Starch: 2098.0g
Gluten powder: 2098.0g
Chinese bee honey: 4197.0g
Making into oxalic acid oral pill 2000 pills, each pill is 5.0g, and each pill contains oxalic acid 3.8 mg.
11. The lactic acid oil-soluble protective mask liquid contains lactic acid as an effective medicinal component, and is characterized in that a lactic acid solvent carrier is an oil-water mutual solution and comprises the following components:
lactic acid: 25.0-42.0g
Glycerol: 9863.0-9732.0g
Benzyl alcohol: 10.0-20.0g
The balance of distilled water, and 10000ml of lactic acid oil-soluble protective mask liquid is prepared.
12. The formic acid oil soluble protective mask liquid contains formic acid as effective medicine component and features that the formic acid solvent carrier is oil-water mutual solvent comprising the following components:
formic acid: 1.0-2.0 g
Glycerol (b): 9799.0-9598.0g
Propylene glycol: 100.0-200.0g
The balance of distilled water, and 10000ml of formic acid oil-soluble protective mask liquid is prepared.
13. An oxalic acid oil-soluble protective mask liquid contains oxalic acid as an effective medicinal component, and is characterized in that an oxalic acid solvent carrier is an oil-water mutual solution and comprises the following components:
oxalic acid: 6.0-12.0g
Glycerol: 9794.0-9588.0g
Propylene glycol: 100.0-200.0g
The balance of distilled water, and 10000ml of oxalic acid oil-soluble protective mask liquid is prepared.
14. The formic acid antibiotic solution for preparing ecological antibiotic inactivated vaccine for resisting novel coronavirus is an inactivated oral vaccine prepared from formic acid oil-oil mutual solution, formic acid oil-water mutual solution and oxalic acid or lactic acid oil-oil mutual solution.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211310635.2A CN115919825A (en) | 2022-01-24 | 2022-01-24 | Medicament using oil-soluble formic acid as antiviral and antibacterial raw material and preparation method thereof |
| CN202210078117.6A CN114642658A (en) | 2022-01-24 | 2022-01-24 | Oil-soluble micromolecule natural biological acid antiviral and antibacterial preparation, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210078117.6A CN114642658A (en) | 2022-01-24 | 2022-01-24 | Oil-soluble micromolecule natural biological acid antiviral and antibacterial preparation, and preparation method and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211310635.2A Division CN115919825A (en) | 2022-01-24 | 2022-01-24 | Medicament using oil-soluble formic acid as antiviral and antibacterial raw material and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114642658A true CN114642658A (en) | 2022-06-21 |
Family
ID=81993068
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210078117.6A Pending CN114642658A (en) | 2022-01-24 | 2022-01-24 | Oil-soluble micromolecule natural biological acid antiviral and antibacterial preparation, and preparation method and application thereof |
| CN202211310635.2A Pending CN115919825A (en) | 2022-01-24 | 2022-01-24 | Medicament using oil-soluble formic acid as antiviral and antibacterial raw material and preparation method thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211310635.2A Pending CN115919825A (en) | 2022-01-24 | 2022-01-24 | Medicament using oil-soluble formic acid as antiviral and antibacterial raw material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN114642658A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133317A (en) * | 1995-11-15 | 2000-10-17 | Hart; Francis J. | Oxalic acid or oxalate composition and method of treatment |
| CN113855668A (en) * | 2020-05-25 | 2021-12-31 | 甘肃芫美药业有限公司 | An antiviral and antibacterial cantharidin preparation, its preparation method, and its application in preventing and treating coronavirus infection |
-
2022
- 2022-01-24 CN CN202210078117.6A patent/CN114642658A/en active Pending
- 2022-01-24 CN CN202211310635.2A patent/CN115919825A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133317A (en) * | 1995-11-15 | 2000-10-17 | Hart; Francis J. | Oxalic acid or oxalate composition and method of treatment |
| CN113855668A (en) * | 2020-05-25 | 2021-12-31 | 甘肃芫美药业有限公司 | An antiviral and antibacterial cantharidin preparation, its preparation method, and its application in preventing and treating coronavirus infection |
Non-Patent Citations (1)
| Title |
|---|
| 高建军: "蚂蚁对人体有什么好处", 《HTTPS://M.BAIDU.COM/BH/M/DETAIL/QR_12321278349671239505》, pages 1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115919825A (en) | 2023-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2756773C2 (en) | Compositions based on cannabidiol and their use methods | |
| CN101623256B (en) | Ivermectin nanoemulsion drug combination and preparation method thereof | |
| US10864188B2 (en) | Anti-microbial composition | |
| KR102149973B1 (en) | Antimicrobial and Antifungal Composition Comprising Eugenol and Gallic Acid as Active Ingredient | |
| CN113855668A (en) | An antiviral and antibacterial cantharidin preparation, its preparation method, and its application in preventing and treating coronavirus infection | |
| US20200179473A1 (en) | Anti-pathogenic compositions | |
| JP2005200339A (en) | Antimicrobial agent | |
| Febriza et al. | The effects of curcumin and vitamin d combination as inhibitor toward Salmonella typhi bacteria growth in vivo | |
| CN114642658A (en) | Oil-soluble micromolecule natural biological acid antiviral and antibacterial preparation, and preparation method and application thereof | |
| KR20120010040A (en) | Naturally occurring antimicrobial composites originated from plants against Bacillus cereus | |
| KR100438209B1 (en) | Complex antimicrobial composition based on carvacrol, thymol, and citral | |
| KR102252009B1 (en) | Antiviral or antibacterial composition containing extracts of Torreya nucifera leaf | |
| KR20240016954A (en) | Composition and method for treating conditions using fractionated honey | |
| JP2023518928A (en) | Compositions for interfering with biofilm formation and for treating biofilm-related disorders | |
| CN108992437B (en) | Use of lauroyl arginine ethyl ester as veterinary antibacterial agent | |
| CN112741826A (en) | New application of niclosamide | |
| US20030158126A1 (en) | Method of treatment for fungal infections with a synergistic formulation of antifungal agents | |
| KR102208837B1 (en) | Composition for inhibiting adhesion, invasion of bacteria or antibacterial resistance comprising methyl gallate and fluoroquinolone antibacterial agent | |
| RU2614730C1 (en) | Antibacterial agents and method for treating intestinal yersiniosis or pseudotuberculosis, or colibacillosis | |
| CN114917285B (en) | Application of polysaccharide compound in medicine for preventing and treating respiratory tract virus infection | |
| RU2753606C1 (en) | Antibacterial humic agent | |
| RU2722272C1 (en) | Agent for treating and preventing nematodosis and cestodiasis in small domestic animals | |
| GOLEN et al. | Effectıveness Of Propolıs And Nıgella Satıva Agaınst The Effects Of Antımıcrobıal Resıstance | |
| Habib Adam et al. | The Phytochemical Tactics for Battling Antibiotic Resistance in Microbes: Secondary Metabolites and Nano Antibiotics Methods | |
| AU2017100714A4 (en) | A Composition Containing Tea Tree Oil and Uses Therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |